Migdal Insurance & Financial Holdings Ltd. Buys 300,000 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Migdal Insurance & Financial Holdings Ltd. grew its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 1.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,335,422 shares of the company’s stock after purchasing an additional 300,000 shares during the quarter. Teva Pharmaceutical Industries makes up 5.7% of Migdal Insurance & Financial Holdings Ltd.’s holdings, making the stock its biggest position. Migdal Insurance & Financial Holdings Ltd. owned about 2.32% of Teva Pharmaceutical Industries worth $404,775,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of TEVA. FMR LLC boosted its position in Teva Pharmaceutical Industries by 30.7% during the fourth quarter. FMR LLC now owns 81,983,231 shares of the company’s stock worth $1,806,910,000 after acquiring an additional 19,242,468 shares during the last quarter. Ion Asset Management Ltd. boosted its holdings in Teva Pharmaceutical Industries by 1.1% in the 4th quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company’s stock valued at $807,766,000 after purchasing an additional 409,778 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in Teva Pharmaceutical Industries by 197,885.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company’s stock valued at $338,989,000 after purchasing an additional 22,044,407 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Teva Pharmaceutical Industries by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 9,281,052 shares of the company’s stock valued at $203,642,000 after purchasing an additional 489,041 shares during the last quarter. Finally, Duquesne Family Office LLC boosted its holdings in Teva Pharmaceutical Industries by 530.1% in the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company’s stock valued at $198,303,000 after purchasing an additional 7,569,450 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on TEVA. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $21.00 to $23.00 in a report on Monday, May 12th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a “buy” rating and a $25.00 price target on the stock. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a “buy” rating and a $24.00 price target on the stock. Finally, Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $24.71.

Teva Pharmaceutical Industries Trading Up 0.4%

Shares of NYSE:TEVA opened at $16.38 on Friday. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $22.80. The company’s 50 day moving average is $17.02 and its two-hundred day moving average is $17.02. The company has a current ratio of 1.03, a quick ratio of 0.74 and a debt-to-equity ratio of 2.59. The company has a market cap of $18.78 billion, a PE ratio of -14.24, a P/E/G ratio of 0.94 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The company had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. During the same period in the prior year, the firm posted $0.48 EPS. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. Equities analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Matthew Shields sold 6,206 shares of the stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president directly owned 9,989 shares of the company’s stock, valued at $170,012.78. This trade represents a 38.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.49% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.